Observational studyThoracic cancer2026
Prospective Multicenter Observational Study of Anlotinib in Advanced Non-Small Cell Lung Cancer: Real-World Evidence From China.
Observational study in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04871997 (A Real-world Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundAnlotinib has shown remarkable efficacy in later-line treatment of advanced non-small cell lung cancer (NSCLC). This prospective real-world study evaluated its efficacy and safety in routine clinical practice.
methodsPatients from 13 centers in China received anlotinib (8-12 mg) once daily on days 1-14 of a 21-day cycle until disease progression, death, or unacceptable toxicity. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.
resultsFrom July 2019 to October 2021, 352 of 373 enrolled patients received ≥ 2 cycles of anlotinib. Median follow-up was 35.5 months. Median PFS and OS were 5.8 months (95% CI, 5.0-6.4) and 11.3 months (95% CI, 9.9-13.1), respectively. ORR and DCR were 19.3% and 84.4%. Multivariable analysis indicated that age ≥ 70 years was independently associated with poorer OS, though a clinically meaningful benefit remained (PFS, 5.9 months; OS, 9.6 months). Efficacy appeared generally similar regardless of baseline brain metastases. Median PFS and OS were 6.3 and 12.7 months in the second-line setting, and 5.5 and 11.3 months in the≥ third-line setting. Treatment-related adverse events occurred in 10.5%, with grade ≥ 3 events in 1.4%; no treatment-related deaths were observed.
conclusionIn this real-world cohort, anlotinib demonstrated effectiveness and acceptable tolerability in advanced NSCLC. Given the observational design, exploratory analyses-including age, treatment line, and baseline brain metastases-should be interpreted with caution. These findings complement limited existing real-world data and may inform future clinical research and decision-making.
trial registrationClinicalTrials.gov identifier: NCT04871997.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.